Immunotherapy represented by anti-PD-1/PD-L1 has revolutionized the paradigm of cancer therapy, however, only about 25% of patients with solid tumors benefit effectively and persistently from anti-PD-1/PD-L1 [7]. The gene discussed is CD274; the disease is cancer.